Company: LDDD
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001213900-25-013782
Chunk: 209

Company: Longduoduo Co Ltd
Filing Date: 2025-02-14
Form: 10-Q
Item: Part II, Item 8
Chunk 209
---
,659  
     (758,519) 
     (40)%
  
    Loss from operations 
     602,574  
     395,485  
     207,089  
     52%
  
    Other income (expense), net 
     5,421  
     (136,584) 
     142,005  
     (104)%
  
    Loss before income taxes 
     607,995  
     258,901  
     349,094  
     135%
  
    Income tax 
     106,396  
     76,073  
     30,323  
     40%
  
    Net Loss 
    $501,599  
    $182,828  
    $318,771  
     174%

2

During the three months ended December 31, 2024, our total revenue
was $1,775,495, of which $28,781 was attributable to the sale of healthcare services, primarily derived from sales of “Immunological
Ozonated Autohemotherapy”, “Meridian-regulating and Consciousness-restoring Iatrotechnics”, “Assay”, “PRP”
and other healthcare services. The remaining $1,775,495 of revenue was attributable to commissions earned by the Company from its service
as sales agent for Honghai. In June of 2023, the Company began to engage in the sales agent business and focused on the sales of preventive
healthcare solutions administered by Honghai, with whom we have a Sales Agency Agreement. As of December 31, 2024, we operate through
five entities: Longduoduo Health Technology, Tianju, Qingguo, Rongbin and Chengheng, which are established in Ordos, Ulanqab, Huhhot,
Baotou and Ordos, respectively, which include four of the largest cities in Inner Mongolia, China.

Quarter to quarter revenue
fell by 24% as compared with the operating revenue of $2,340,543 for the three months ended December 31, 2023. The decrease was primarily
attributable to the fact that Neimenggu Province was emerging from the pandemic during the three months ended December 31, 2023. A large
number of customers received services during that quarter that they had earlier paid for but could not receive. This resulted in a